Hypertriglyceridemia Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Hypertriglyceridemia pipeline constitutes 20+ key companies continuously working towards developing 20+ Hypertriglyceridemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hypertriglyceridemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market.
The Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Hypertriglyceridemia Pipeline Report:
• Hypertriglyceridemia Companies across the globe are diligently working toward developing novel Hypertriglyceridemia treatment therapies with a considerable amount of success over the years.
• Hypertriglyceridemia companies working in the treatment market are Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others, are developing therapies for the Hypertriglyceridemia treatment
• Emerging Hypertriglyceridemia therapies in the different phases of clinical trials are- LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others are expected to have a significant impact on the Hypertriglyceridemia market in the coming years.
• On April 2024, Arrowhead Pharmaceuticals announced results of a Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia.
• On March 2024, Marea Therapeutics announced results of a Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction.
• In December 2022, Ionis Pharmaceuticals initiated an open-label extension study ofolezarsen (ISIS 678354) administered subcutaneously to patients with severe hypertriglyceridemia(SHTG). This is a multi-center, open-label study of up to 700 participants with SHTG who would berolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable.
• In August 2022, Ionis Pharmaceuticals initiated a randomized, double-blind, placebocontrolled, Phase III study of olezarsen (ISIS 678354) administered subcutaneously to patients withsevere hypertriglyceridemia.

Hypertriglyceridemia Overview
Hypertriglyceridemia is a condition characterized by high levels of triglycerides in the blood, which are a type of fat found in the bloodstream. While triglycerides are essential for storing energy, elevated levels can increase the risk of cardiovascular diseases like heart attack and stroke.

Several factors can contribute to hypertriglyceridemia, including genetics, diet, obesity, sedentary lifestyle, alcohol consumption, diabetes, and certain medications. Symptoms are often absent, but in severe cases, individuals may experience abdominal pain, pancreatitis (inflammation of the pancreas), and eruptive xanthomas (fatty deposits under the skin).

Hypertriglyceridemia Diagnosis is typically made through a blood test measuring triglyceride levels after fasting for 8 to 12 hours. Treatment involves lifestyle modifications such as adopting a healthy diet low in sugar, refined carbohydrates, and saturated fats, regular exercise, weight management, and limiting alcohol intake. In some cases, medications like statins, fibrates, omega-3 fatty acids, or niacin may be prescribed to help lower triglyceride levels.

Hypertriglyceridemia Prevention strategies include maintaining a healthy weight, exercising regularly, limiting alcohol intake, and consuming a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Managing underlying conditions like diabetes and hypothyroidism is also crucial in preventing and managing hypertriglyceridemia. Regular monitoring and follow-up with healthcare providers are essential for individuals with this condition.

Get a Free Sample PDF Report to know more about Hypertriglyceridemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Hypertriglyceridemia Drugs Under Different Phases of Clinical Development Include:
• LY3875383: Eli Lilly and Company
• TLC-2716: OrsoBio
• MAR001: Marea Therapeutics
• ARO-APOC3: Arrowhead Pharmaceuticals
• NST-1024: NorthSea Therapeutics
• Olezarsen: Ionis Pharmaceuticals
• Pegozafermin: 89bio, Inc.

Hypertriglyceridemia Route of Administration
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Hypertriglyceridemia Molecule Type
Hypertriglyceridemia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Hypertriglyceridemia Pipeline Therapeutics Assessment
• Hypertriglyceridemia Assessment by Product Type
• Hypertriglyceridemia By Stage and Product Type
• Hypertriglyceridemia Assessment by Route of Administration
• Hypertriglyceridemia By Stage and Route of Administration
• Hypertriglyceridemia Assessment by Molecule Type
• Hypertriglyceridemia by Stage and Molecule Type

DelveInsight's Hypertriglyceridemia Pipeline Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hypertriglyceridemia product details are provided in the report. Download the Hypertriglyceridemia pipeline report to learn more about the emerging Hypertriglyceridemia therapies at:
https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Hypertriglyceridemia Therapeutics Market include:
Key companies developing therapies for Hypertriglyceridemia are - Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others

Hypertriglyceridemia Pipeline Analysis:
The Hypertriglyceridemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertriglyceridemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia Treatment.
• Hypertriglyceridemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypertriglyceridemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertriglyceridemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypertriglyceridemia drugs and therapies-
https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hypertriglyceridemia Pipeline Market Drivers
• Increased Consumption of Unhealthy Diet, increase in research and developmental activities are some of the important factors that are fueling the Hypertriglyceridemia Market.

Hypertriglyceridemia Pipeline Market Barriers
• However, high-cost associated with the disease, limited awareness about the disease and other factors are creating obstacles in the Hypertriglyceridemia Market growth.

Scope of Hypertriglyceridemia Pipeline Drug Insight
• Coverage: Global
• Key Hypertriglyceridemia Companies: Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others
• Key Hypertriglyceridemia Therapies: LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others
• Hypertriglyceridemia Therapeutic Assessment: Hypertriglyceridemia current marketed and Hypertriglyceridemia emerging therapies
• Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia market drivers and Hypertriglyceridemia market barriers

Request for Sample PDF Report for Hypertriglyceridemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Hypertriglyceridemia Report Introduction
2. Hypertriglyceridemia Executive Summary
3. Hypertriglyceridemia Overview
4. Hypertriglyceridemia- Analytical Perspective In-depth Commercial Assessment
5. Hypertriglyceridemia Pipeline Therapeutics
6. Hypertriglyceridemia Late Stage Products (Phase II/III)
7. Hypertriglyceridemia Mid Stage Products (Phase II)
8. Hypertriglyceridemia Early Stage Products (Phase I)
9. Hypertriglyceridemia Preclinical Stage Products
10. Hypertriglyceridemia Therapeutics Assessment
11. Hypertriglyceridemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypertriglyceridemia Key Companies
14. Hypertriglyceridemia Key Products
15. Hypertriglyceridemia Unmet Needs
16 . Hypertriglyceridemia Market Drivers and Barriers
17. Hypertriglyceridemia Future Perspectives and Conclusion
18. Hypertriglyceridemia Analyst Views
19. Appendix
20. About DelveInsight

Trending Report:
• Contact Dermatitis Market: https://www.delveinsight.com/infographics/contact-dermatitis-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-market
• Dlbcl Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report
• Generalized Anxiety Disorder Gad Market: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Hyperkalemia Market: https://www.delveinsight.com/report-store/hyperkalemia-market
• Hyperopia Market: https://www.delveinsight.com/report-store/hyperopia-market
• Metabolic Acidosis Market: https://www.delveinsight.com/blog/metabolic-acidosis-market
• Metastatic Bone Pain Market: https://www.delveinsight.com/report-store/metastatic-bone-pain-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Nonmuscle Invasive Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Osteochondromas Market: https://www.delveinsight.com/report-store/osteochondromas-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Pcsk9 Inhibitor Market: https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Rett Syndrome Market: https://www.delveinsight.com/report-store/rett-syndrome-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.